KTRA Key Statistics, Chart & Performance
The current stock price of KTRA is 0.2154 USD. In the past month the price increased by 18.55%. In the past year, price decreased by -94.63%.
KTRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KTRA. When comparing the yearly performance of all stocks, KTRA is a bad performer in the overall market: 96.29% of all stocks are doing better.
KTRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KTRA. The financial health of KTRA is average, but there are quite some concerns on its profitability.
KTRA Financial Highlights
Over the last trailing twelve months KTRA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS increased by 77.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.12% | ||
| ROE | -226.35% | ||
| Debt/Equity | 0 |
KTRA Forecast & Estimates
6 analysts have analysed KTRA and the average price target is 14.28 USD. This implies a price increase of 6529.53% is expected in the next year compared to the current price of 0.2154.
KTRA Ownership
KTRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About KTRA
Company Profile
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 2 full-time employees. The company went IPO on 2016-07-12. The firm's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. The company has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.
Company Info
KINTARA THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 150, Suite 200
San Diego CALIFORNIA 92130 US
CEO: Saiid Zarrabian
Employees: 2
Phone: 18583504364
KINTARA THERAPEUTICS INC / KTRA FAQ
What does KTRA do?
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 2 full-time employees. The company went IPO on 2016-07-12. The firm's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. The company has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.
What is the current price of KTRA stock?
The current stock price of KTRA is 0.2154 USD. The price decreased by -6.31% in the last trading session.
Does KINTARA THERAPEUTICS INC pay dividends?
KTRA does not pay a dividend.
How is the ChartMill rating for KINTARA THERAPEUTICS INC?
KTRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does KINTARA THERAPEUTICS INC belong to?
KINTARA THERAPEUTICS INC (KTRA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for KTRA stock?
KINTARA THERAPEUTICS INC (KTRA) currently has 2 employees.
Can you provide the market cap for KINTARA THERAPEUTICS INC?
KINTARA THERAPEUTICS INC (KTRA) has a market capitalization of 11.99M USD. This makes KTRA a Nano Cap stock.